free web stats

Law Offices of Thomas J. Lamb

NAION With Ozempic, Wegovy, Mounjaro, or Zepbound Use: Why Are There Still No Warnings?

By

Numerous medical studies have been published in the past couple of years about non-arteritic anterior ischemic optic neuropathy (NAION) with Ozempic, Wegovy, Mounjaro, or Zepbound use resulting in sudden vision loss.

Despite this drug safety information, the current Prescribing Information documents or drug labels in the US for these four increasingly popular drugs still do not have any warnings for doctors or patients about NAION and vision loss as of October 2026.

Before we point out two recent medical news articles relevant to NAION with Ozempic, Wegovy, Mounjaro, or Zepbound use, and whether their respective drug labels should have NAION and vision loss warnings, here are a couple of earlier pieces we wrote about those issues:

NAION Linked To Zepbound, Mounjaro, Ozempic, Wegovy: 2026 News Update (5/22/26)

Ozempic Eye Side Effect NAION Warnings Update July 2026 (7/28/26)

Now for the two recent medical news articles about NAION with Ozempic, Wegovy, Mounjaro, or Zepbound use, as well as the present lack of any NAION and vision loss warnings here in the US:

  1. “GLP-1s may be linked to vision loss, but overall risk ‘very, very low’“, published online October 2, 2026, by Healio Primary Care Optometry News; and
  2. “GLP-1s and NAION: Do Patients Need a Warning?“, published online October 2, 2026, by Medscape Medical News.

From talking to numerous people who have vision loss due to NAION diagnosed while using Ozempic and Wegovy (which are both semaglutide-containing drugs), as well as Mounjaro and Zepbound (which are both tirzepatide-containing drugs), we can tell you that many of these people said they were disappointed there were no NAION and vision loss warnings. Moreover, some of those people were understandably angry about this failure by the responsible drug companies.

We have been investigating drug injury lawsuits against those drug companies for patients who have vision loss due to NAION with Ozempic, Wegovy, Mounjaro, or Zepbound use.

If you have been diagnosed with NAION due to Ozempic, Wegovy, Mounjaro, or Zepbound use, you may want to submit a Case Evaluation Form online to get a free review of your potential NAION lawsuit:

Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form

Zepbound / Mounjaro Eye Side Effect NAION Case Evaluation Form

If you would prefer to discuss your potential NAION lawsuit with drug injury lawyer Tom Lamb, send him an email at TJL@LambLawOffice.com or call 910-256-2971.

[Read the article in full at Drug Injury Watch]

Ozempic / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Mounjaro / Zepbound

Free Case Evaluation

Strictly Confidential, No Obligation

Mounjaro, Ozempic Vision Loss Lawsuits Filings Increase – 2026 News Reports

By

The number of vision loss lawsuits filed by patients using Ozempic and Mounjaro has increased in 2026, according to major TV news shows and national newspapers. The drug injury lawsuits involve nonarteritic anterior ischemic optic neuropathy (NAION), an eye-related side effect of those two medications and others in the glucagon-like peptide-1 receptor agonists (GLP-1) class of drugs.

We begin with a September 21, 2026 NBC News report (video), “Hundreds of lawsuits filed against some GLP-1 Makers over vision loss”.

And from among the many newspaper articles about these vision loss lawsuits, we get the following from a September 18, 2026 article published by the Wall Street Journal, “Patients Sue GLP-1 Drugmakers Over Risk of Sudden Vision Loss”:

Michelle Fennell was sitting at her desk when her right eye started feeling heavy. Suddenly, it was blurry and her peripheral vision waned. It felt like she was looking through a fishbowl; she could see straight ahead but not to her right or down.

Two weeks later, a doctor diagnosed Fennell, 53 years old, with nonarteritic anterior ischemic optic neuropathy, or NAION, a condition that leads to sudden, often permanent vision loss.

The doctor asked what medicines she was taking. “He said right away, stop taking Ozempic,” to protect her remaining vision, said Fennell, who started taking the drug to treat her Type 2 diabetes six months prior. “I was shocked.”…

Fennell is one of dozens of people suing Novo, maker of the popular weight-loss and diabetes drugs Wegovy and Ozempic, claiming the medication caused this side effect

As background, to better understand what is behind this increase in vision loss lawsuit filings:

  • The active ingredient semaglutide has been linked to NAION; Ozempic as well as Wegovy are semaglutide-containing drugs.
  • The active ingredient tirzepatide has been linked to NAION; Mounjaro as well as Zepbound are tirzepatide-containing drugs.
  • NAION is sometimes called an “eye stroke,” and it occurs when the optic nerve does not receive enough blood flow.
  • NAION typically causes sudden vision loss and, in severe cases, can lead to blindness.
  • There are currently no proven treatments for NAION.
  • As of today (September 23, 2026), the drug labels for Ozempic, Wegovy, Mounjaro, and Zepbound do not include warnings about the NAION eye-related side effect of these medications and other GLP-1 drugs.
  • Based on this failure to warn about NAION and the vision loss resulting from this serious side effect, NAION drug injury lawsuits have been filed against the responsible pharmaceutical companies seeking legal compensation for patients diagnosed with NAION and suffering vision loss.

Long before these 2026 newspaper articles and TV news reports about the vision loss lawsuit filings increase — since back in the summer of 2024 — we have been investigating drug injury lawsuits for patients who used Ozempic, Wegovy, Mounjaro, or Zepbound and have been diagnosed with NAION, or an “eye stroke”.

These NAION vision loss lawsuits for patients using Ozempic or Wegovy would be filed against Novo Nordisk, which last week announced it had shortened its name to “Novo”. For more, see our Drug Injury Law information page for this set of vision loss lawsuits: Eye-related Side Effects of Ozempic, Wegovy, and Rybelsus With Vision Loss.

Drug injury NAION vision loss lawsuits involving Mounjaro or Zepbound for patients with vision loss would be filed against Eli Lilly. For more about this set of vision loss lawsuits: Zepbound and Mounjaro Eye Side Effect NAION Information Page.

For these vision loss lawsuits, we offer an online case evaluation service that is free and confidential, and without obligation:

Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form

Zepbound / Mounjaro Eye Side Effect NAION Case Evaluation Form

Experienced drug injury attorney Tom Lamb reviews each one of these online Case Evaluation Form submissions. Or call him at 910-256-2971 to discuss a possible NAION vision loss lawsuit.

[Read the article in full at Drug Injury Watch]

Ozempic / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Mounjaro / Zepbound

Free Case Evaluation

Strictly Confidential, No Obligation

NAION Cases Filed in Courts for Vision Loss Legal Compensation

By

We are handling NAION cases filed in courts around the country to help people obtain legal compensation for vision loss.

People using Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound who seek legal compensation for vision loss due to nonarteritic anterior ischemic optic neuropathy (NAION) have filed more than 200 lawsuits as of August 2026.

In December 2025, all the federal NAION cases filed in courts were consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPML). This JPML ruling appointed U.S. District Judge Karen S. Marston, in the Eastern District of Pennsylvania, to preside over this consolidated federal court NAION litigation: MDL-3163 IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation.

There are additional NAION cases filed in courts around the country on behalf of people seeking legal compensation for vision loss. Those NAION lawsuits are pending in numerous different state courts.

The NAION vision loss cases in each of those courts involve, for the most part, these popular drugs used for diabetes or weight loss: Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound.

We have been reporting on the medical and legal developments pertinent to these NAION cases filed in courts for more than two years, since July 2024.

Here is a list of some past relevant Drug Injury Law articles you may want to read for background information:

More vision loss cases are being investigated, so there will be more NAION cases filed in courts during 2026 and the next couple of years.

People diagnosed with NAION who suffered vision loss while using Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound can submit an online Case Evaluation Form to be reviewed by drug injury lawyer Tom Lamb:

Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form

Zepbound / Mounjaro Eye Side Effect NAION Case Evaluation Form

Or, if you prefer, call 910-256-2971 to speak directly to attorney Tom Lamb about a possible Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound vision-loss legal compensation case involving NAION.

[Read the article in full at source]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Mounjaro / Zepbound

Free Case Evaluation

Strictly Confidential, No Obligation

Ozempic Eye Side Effect NAION Warnings Update July 2026

By

Non-arteritic anterior ischemic optic neuropathy (NAION) is an eye side effect associated with Ozempic in numerous medical reports over the past couple of years. This article provides an Ozempic eye side effect NAION warnings update as of late July 2026 covering the US and some other countries around the world.

On July 23, 2026, the Australian drug regulatory agency Therapeutic Goods Administration (TGA) issued a Medicines Safety Update titled “GLP-1 RAs and rare vision disorder”,  which pointed out that the Ozempic eye side NAION warnings would be added in Australia.

Further, in that July 2026 TGA Medicines Safety Update where the Ozempic NAION risk is highlighted, one finds a list of earlier actions taken by some other international drug regulators:

However, the current (Revised: 5/2026 version) Ozempic Prescribing Information, or drug label, in the United States still does not include warnings about Ozempic-related eye side effects, such as NAION.

Drug injury lawsuits involving Ozempic for patients with vision loss due to NAION are being filed in the US against Novo Nordisk for its failure to include Ozempic eye side effect NAION warnings.

We emphasize that because there are no warnings in the current Ozempic drug label about an increased risk of NAION, those Ozempic lawsuits are not being filed against the doctors who prescribed Ozempic to the people who have suffered vision loss due to this serious eye-related side effect.

People diagnosed with NAION can submit an Ozempic Vision Loss Case Evaluation Form online. Or, if you prefer, call 910-256-2971 to talk with drug injury lawyer Tom Lamb about a possible Ozempic NAION lawsuit.

[Read the article in full at Drug Injury Watch]

Ozempic

Free Case Evaluation

Strictly Confidential, No Obligation

Semaglutide NAION Lawsuits in 2026 for Wegovy, Rybelsus, Ozempic Vision Loss

By

Semaglutide NAION lawsuits in 2026 are based on the failure to warn about this serious eye side effect. These court cases seek legal compensation for patients diagnosed with NAION vision loss or blindness.

In more detail, lawsuits for Wegovy, Rybelsus, and Ozempic vision loss cases involving semaglutide-associated nonarteritic anterior ischemic optic neuropathy (NAION) are filed against Novo Nordisk, the pharmaceutical company responsible for those three semaglutide-containing GLP-1 drugs. This is because, at present, there is no warning about semaglutide-associated NAION in the current drug labels for Ozempic, Rybelsus, and Wegovy.

Some new important evidence for these semaglutide NAION lawsuits involving Ozempic, Rybelsus, and Wegovy is found in this medical journal article published in May 2026 by PLOS Medicine, “Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies“.

From the Abstract for this recent PLOS Medicine medical journal article relevant to Wegovy, Rybelsus, and Ozempic NAION vision loss cases:

Conclusions: Our findings suggest a possible association between semaglutide use and an increased risk of NAION in patients with [type 2 diabetes (T2DM)]. Although the absolute risk is low, clinicians should be aware of this potential adverse event, particularly in individuals at increased baseline risk for optic neuropathies. While these findings support current recommendations to discontinue semaglutide in patients diagnosed with NAION, the certainty of the available evidence is low, underscoring the need for further high-quality studies to clarify this association.

However, as we pointed out above, the current drug labels for Ozempic, Wegovy, and Rybelsus do not have any warning about semaglutide-associated NAION vision loss or blindness as a possible side effect.

As seen by this list of earlier Drug Injury Law articles, our law firm is very familiar with the semaglutide-associated NAION side effects of Ozempic, Wegovy, and Rybelsus:

In addition, our law firm has experience handling semaglutide NAION lawsuits involving Wegovy, Rybelsus, and Ozempic vision loss or blindness cases for patients.

Patients diagnosed with NAION-related vision loss or blindness can submit an Ozempic/Wegovy/Rybelsus Vision Loss Case Evaluation Form online. Or, if you prefer, call 910-256-2971 to talk with drug injury lawyer Tom Lamb about semaglutide NAION lawsuits.

[Read the article in full at Drug Injury Watch]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

NAION Linked To Zepbound, Mounjaro, Ozempic, Wegovy: 2026 News Update

By

The eye side effect non-arteritic anterior ischemic optic neuropathy (NAION) linked to Zepbound, Mounjaro, Ozempic, Wegovy, and other glucagon-like peptide-1 receptor agonists (GLP-1RA) drugs is the focus of an April 2026 medical study report published online by JAMA Network Open.

This medical study report, “GLP-1 Receptor Agonists or SGLT2 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy“, presents a 2025 analysis of 2017 – 2023 health records from the US Department of Veterans Affairs (VA) done to investigate the rate of this NAION eye side effect that users of Zepbound, Mounjaro, Ozempic, Wegovy, and other GLP-1RA drugs have reported.

When all was said and done, the authors of this 2026 medical study report about NAION concluded:

In this large cohort study, [Zepbound, Mounjaro, Ozempic, Wegovy, and other GLP-1RA drugs] use was associated with a modestly increased risk of NAION compared with [sodium-glucose cotransporter-2 inhibitors (SGLT2i) drugs] use. While the absolute risk remains low, the specificity of this finding may warrant heightened vigilance.

NAION linked to Zepbound, Mounjaro, Ozempic, Wegovy, and other GLP-1RA drugs is an issue that first came to light in the second part of 2024. For example, two large medical studies from Denmark found that people who used Ozempic had double the risk of developing NAION, which can cause vision loss and blindness.

Drug Injury Lawsuits for NAION Linked to Zepbound, Mounjaro, Ozempic, or Wegovy

In the past couple of years, NAION drug injury lawsuits involving Zepbound, Mounjaro, Ozempic, Wegovy, and other GLP-1RA drugs have been filed against the responsible pharmaceutical companies for their failure to warn patients and doctors about the risk of developing NAION.

For an introduction to the medical and legal aspects of these NAION drug injury lawsuits, here are two relevant Drug Injury Law website links:

We are investigating cases of NAION linked to Zepbound, Mounjaro, Ozempic, Wegovy, and other GLP-1RA drugs for patients as drug injury lawsuits seeking legal compensation for their vision loss. We point out that those NAION lawsuits would not be filed against the patients’ doctors because the pharmaceutical company failed to warn about the NAION eye side effect associated with their drug.

[Read the article in full at Drug Injury Watch]

Mounjaro / Zepbound

Free Case Evaluation

Strictly Confidential, No Obligation

Ozempic /  Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Ozempic and Wegovy NAION Study 2026 Report: Two New Findings

By

A recent Ozempic and Wegovy NAION study made two new findings about people who used Ozempic or Wegovy and then were diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION) as a drug side effect that caused vision loss. The first is that the Wegovy NAION rate is five times that of Ozempic. The second is that for users of Ozempic and Wegovy, NAION was diagnosed in men three times more than in women.

These findings from the Ozempic and Wegovy NAION study were presented in this March 2026 British Journal of Ophthalmology article, “Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk“.

News Articles About

Ozempic and Wegovy NAION Study

Here are three news articles that provide the details and some contextual information about the Ozempic and Wegovy NAION study 2026 report:

“Wegovy May Carry Highest Risk of Blinding Condition Among GLP-1 Drugs“, MedPage Today, 3/10/26

“Wegovy linked to higher risk of eye stroke and vision loss“, BMJ Group, 3/10/26

“Wegovy users have five times greater risk of sudden sight loss than Ozempic users, study finds“, The Guardian, 3/10/26

We have been following the vision side-effect drug safety issue that is the subject of this Ozempic and Wegovy NAION study report since July 2024. During that time, we have investigated possible drug injury lawsuits against Novo Nordisk for patients diagnosed with NAION and who suffered vision loss.

Earlier Posts Related to

Ozempic and Wegovy NAION Study

Related to this Ozempic and Wegovy NAION study 2026 report, here is a list of some of our earlier posts about non-arteritic anterior ischemic optic neuropathy (NAION) associated with the semaglutide-containing drugs Wegovy and Ozempic, as well as Rybelsus, all from Novo Nordisk:

If you have a possible NAION drug injury lawsuit involving one of the semaglutide drugs from Novo Nordisk that you want reviewed, you can submit an Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form online, send an email to TJL@LambLawOffice.com, or call us at 910-256-2971.

[Read the article in full at Drug Injury Watch]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Ozempic-NAION Warnings Should Be In January 2026 Drug Label For New Pill Version

By

We have written about the Ozempic-NAION side effect drug safety issue several times over the past year-and-a-half, and have repeatedly pointed out that NAION is linked to semaglutide, the active ingredient in the currently available Novo Nordisk semaglutide medicines: Ozempic injection, Wegovy injection, Wegovy tablet, and Rybelsus tablet. Further, we have suggested that all these Novo Nordisk semaglutide medicines should have NAION warnings, such that there would be Ozempic-NAION warnings, Wegovy-NAION warnings, and Wegovy-NAION warnings.

But as of late January 2026, when the “Revised: 1/2026” Prescribing Information document for “RYBELSUS and OZEMPIC tablets” was released, none of the drug labels for Novo Nordisk semaglutide medicines included any NAION warnings.

Before providing some information about why we suggest Ozempic-NAION warnings should be in the recently released January 2026 drug label for the new tablet or pill version of Ozempic that will be available in the US later this year, we direct you to this February 4, 2026, Novo Nordisk USA announcement, “Novo Nordisk introduces Ozempic® Pill; Available in the US Q2 2026” for some information about that new drug product.

Ozempic-NAION Warnings Information

Here are two earlier articles from our Drug Injury Watch blog that provide support for this suggestion that there should be Ozempic-NAION warnings included in that January 2026 drug label for the new pill version of Ozempic, soon to be available, as well as the current drug label for the already available, and popular, Ozempic injection:

  1. “Risk of NAION With Semaglutide Medicines is 2 Times Higher Than SGLT2i Diabetes Drugs”  (2/13/2026)
  2. “Wegovy and Ozempic Increase NAION Risk, an Eye Side Effect That Can Result in Blindness”  (10/22/2025)

The failure by Novo Nordisk to have Ozempic-NAION warnings available for doctors who prescribe Ozempic — or Rybelsus, or Wegovy — as well as the people who use these popular Novo Nordisk semaglutide medicines is the basis for drug injury lawsuits that have been filed against this pharmaceutical company on behalf of people diagnosed with non-arteritic anterior ischemic optic neuropathy, or NAION.

If you have been diagnosed with NAION while using one of those Novo Nordisk semaglutide medicines or soon thereafter, you may want to submit an Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form online. It is free, confidential, and there is no obligation.

In the alternative, if you have a possible Wegovy, Rybelsus, or Ozempic NAION drug injury lawsuit that you want evaluated by drug injury attorney Tom Lamb, you can send an email to TJL@LambLawOffice.com or call 910-256-2971.

[Read the article in full at Drug Injury Watch]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Ozempic NAION Risk 200% Higher Than Some Other Diabetes Drugs

By

The semaglutide-containing drug Ozempic has been linked to non-arteritic anterior ischemic optic neuropathy (NAION). A 2026 medical journal article reported that the Ozempic NAION risk 200% higher than that of some other diabetes drugs, such as Invokana (canagliflozin), Jardiance (empagliflozin), and Farxiga (dapagliflozin), which are sodium-glucose cotransporter-2 (SGLT2) inhibitors, also referred to as SGLT2i drugs. Like Ozempic, the SGLT2 inhibitors Invokana, Jardiance, and Farxiga are used to treat Type 2 diabetes.

This article, “New-Onset Nonarteritic Anterior Ischemic Optic Neuropathy and Initiators of Semaglutide in US Veterans With Type 2 Diabetes”, published in February 2026 by the medical journal JAMA Ophthalmology, begins with a “Key Points” part that includes the following:

Question Is semaglutide associated with an increased risk of incidence of nonarteritic anterior ischemic optic neuropathy (NAION) compared with sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with type 2 diabetes?

Findings In this study, among a group of US veterans with type 2 diabetes, initiation of semaglutide was associated with a 2-fold higher risk of incident NAION compared with initiation of an SGLT2i,…

In addition to Ozempic, two other semaglutide-containing drugs are Wegovy and Rybelsus, so this new evidence about the Ozempic NAION risk applies to those drugs, also. We point out that Novo Nordisk is the pharmaceutical company responsible for Ozempic, Wegovy, and Rybelsus.

Ozempic NAION Risk: Earlier Posts

Here are some of the earlier posts relevant to this recently reported medical fact that the Ozempic NAION risk 200% higher than that of some other diabetes drugs:

The current drug labels for Ozempic, Wegovy, and Rybelsus do not warn about non-arteritic anterior ischemic optic neuropathy (NAION) as a possible eye-related side effect that can cause vision loss.

Given that situation, together with newly reported evidence of the Ozempic NAION risk 200% higher than that of some other diabetes drugs, we are handling drug injury lawsuits for patients who developed the NAION eye-related side effect associated with Ozempic, Wegovy, and Rybelsus.

Drug injury lawsuits involving Ozempic, Wegovy, and Rybelsus for patients diagnosed with NAION would be filed against Novo Nordisk for its failure to warn about NAION as a possible side effect.

If you have a possible Rybelsus, Wegovy, or Ozempic NAION case that you would like to have investigated for a drug injury lawsuit, you can submit an online Case Evaluation Form. If you prefer, send attorney Tom Lamb an email (TJL@LambLawOffice.com) or call him (910-256-2971).

[Read the article in full at Drug Injury Watch]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

A Rybelsus Blood Clots DVT Case

By

We have been investigating Ozempic, Wegovy, and Rybelsus blood clots, deep vein thrombosis (DVT), and pulmonary embolism (PE) cases as possible drug injury lawsuits against the pharmaceutical company Novo Nordisk. Starting in or about 2021, Ozempic, Wegovy, and Rybelsus — the three Novo Nordisk semaglutide-containing drugs — have been associated with a significantly increased risk of blood clots. In this post, we point out a recent medical journal article that discusses a Rybelsus blood clots DVT case involving a teenage boy.

From the Abstract part of this medical journal article, “Deep Venous Thrombosis Within Two Weeks of Initiating Oral Semaglutide (Rybelsus): A Case Report”, we get some information about the Rybelsus blood clots DVT case:

We report the case of a 16-year-old male with mild conventional risk factors for thrombosis [overweight body mass index (BMI) and prolonged sedentary behavior] who developed acute left lower extremity deep venous thrombosis (DVT) within two weeks of initiating [Rybelsus (oral semaglutide)] for weight reduction without medical supervision. He presented with progressive leg pain and swelling, and duplex ultrasonography revealed thrombosis of the distal superficial femoral and popliteal veins….

This case suggests a possible association between [Rybelsus (oral semaglutide)] and venous thrombosis in an adolescent, highlighting the need for careful supervision during off-label use.

We have written previously about the Ozempic, Wegovy, and Rybelsus blood clots side effects of deep vein thrombosis (DVT) and pulmonary embolism (PE):

Semaglutide-Related Blood Clots Cases: Ozempic, Wegovy, and Rybelsus

Deep Vein Thrombosis When Using Wegovy, Rybelsus, or Ozempic

Wegovy / Rybelsus / Ozempic Deep Vein Thrombosis Side Effects

We can assist individuals with a Rybelsus blood clots DVT case if they submit an online Case Evaluation Form or call us at 910-256-2971.

[Read the article in full at Drug Injury Watch]

Ozempic / Rybelsus / Wegovy

Free Case Evaluation

Strictly Confidential, No Obligation

Our Other Websites

DrugInjuryWatch.com

LambLawOffice.com

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971
TJL@LambLawOffice.com